References
- Sung H, Ferlay J, Siegel RL, et al. Global c ancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021 May;71(3):209–249. DOI:https://doi.org/10.3322/caac.21660.
- Siegel RL, Miller KD, Fuchs HE, et al. Cancer Statistics, 2021. CA Cancer J Clin. 2021 Jan;71(1):7–33. DOI:https://doi.org/10.3322/caac.21654.
- Rahib L, Smith BD, Aizenberg R, et al. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014 Jun 1;74(11):2913–2921.
- Ducreux M, Cuhna AS, Caramella C, et al. Cancer of the pancreas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015 Sep;26(Suppl 5):v56–68. DOI:https://doi.org/10.1093/annonc/mdv295.
- Parkin DM, Boyd L, Walker LC. The fraction of cancer attributable to lifestyle and environmental factors in the UK in 2010. Br J Cancer. 2011 Dec 6;105(Suppl 2):S77–81.
- Hidalgo M. Pancreatic cancer. N Engl J Med. 2010 Apr 29;362(17):1605–1617.
- Neoptolemos JP, Kleeff J, Michl P, et al. Therapeutic developments in pancreatic cancer: current and future perspectives. Nat Rev Gastroenterol Hepatol. 2018 Jun;15(6):333–348. DOI:https://doi.org/10.1038/s41575-018-0005-x.
- Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011 May 12;364(19):1817–1825.
- Hruban RH, Gaida MM, Thompson E, et al. Why is pancreatic cancer so deadly? The pathologist’s view. J Pathol. 2019 Jun;248(2):131–141. DOI:https://doi.org/10.1002/path.5260.
- Sohal DPSDPS, Kennedy EB, Khorana A, et al. Metastatic pancreatic cancer: ASCO clinical practice guideline update. J Clin Oncol. 2018 Aug 20;36(24):2545–2556.
- Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013 Oct 31;369(18):1691–1703.
- Wainberg ZA, Bekaii-Saab TS, Hubner R, et al. NAPOLI-3: an open-label, randomized, phase III study of first-line liposomal irinotecan + 5-fluorouracil/leucovorin + oxaliplatin versus nab-paclitaxel + gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma. J clin oncol. 2020;38(15_suppl): TPS4661. DOI:https://doi.org/10.1200/JCO.2020.38.15_suppl.TPS4661.
- Wang-Gillam A, Hubner RA, Siveke JT, et al. NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: final overall survival analysis and characteristics of long-term survivors. Eur J Cancer. 2019 Feb;108:78–87.
- Kalra AV, Kim J, Klinz SG, et al. Preclinical activity of nanoliposomal irinotecan is governed by tumor deposition and intratumor prodrug conversion. Cancer Res. 2014 Dec 1;74(23):7003–7013.
- Hurwitz HI, Tan BR, Reeves JA, et al. Phase II randomized trial of sequential or concurrent FOLFOXIRI-bevacizumab versus folfox-bevacizumab for metastatic colorectal cancer (STEAM). Oncologist. 2019 Jul;24(7):921–932. DOI:https://doi.org/10.1634/theoncologist.2018-0344.
- Kobayakawa M, Kojima Y. Tegafur/gimeracil/oteracil (S-1) approved for the treatment of advanced gastric cancer in adults when given in combination with cisplatin: a review comparing it with other fluoropyrimidine-based therapies. Onco Targets Ther. 2011;4:193–201.
- Chiang N-J, Shan Y-S, Bai L-Y, et al. TCOG T5217 trial: a phase II randomized study of SLOG versus modified FOLFIRINOX as the first-line treatment in locally advanced or metastatic pancreatic ductal adenocarcinoma. J clin oncol. 2021;39(15_suppl):4143. DOI:https://doi.org/10.1200/JCO.2021.39.15_suppl.4143.
- Dahan L, Williet N, and Le Malicot K, et al. Randomized phase ii trial evaluating two sequential treatments in first line of metastatic pancreatic cancer: results of the PANOPTIMOX-PRODIGE 35 trial. J Clin Oncol. 2021;39(29) :3242–3250.
- Wang-Gillam A, Li CP, Bodoky G, et al. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet. 2016 Feb 6;387(10018):545–557.
- Portal A, Pernot S, Tougeron D, et al. Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort. Br J Cancer. 2015 Sep 29;113(7):989–995.
- Löhr JM, Haas SL, Bechstein WO, et al. Cationic liposomal paclitaxel plus gemcitabine or gemcitabine alone in patients with advanced pancreatic cancer: a randomized controlled phase II trial. Ann Oncol. 2012 May;23(5):1214–1222. DOI:https://doi.org/10.1093/annonc/mdr379.
- Chen L-T, Su M-H. EndoTAG-1 plus gemcitabine versus gemcitabine alone in patients with measurable locally advanced and/or metastatic adenocarcinoma of the pancreas failed on FOLFIRINOX treatment (NCT03126435). J clin oncol. 2020;38(15_suppl): TPS4669.
- Greenstein AE, Hunt HJ. Glucocorticoid receptor antagonism promotes apoptosis in solid tumor cells. Oncotarget. 2021 Jun 22;12(13):1243–1255.
- Munster PN, Sachdev JC, Fleming GF, et al. Relacorilant (RELA) with nab-paclitaxel (NP): safety and activity in patients with pancreatic ductal adenocarcinoma (PDAC) and ovarian cancer (OvCA). J clin oncol. 2019;37(15_suppl):4130. DOI:https://doi.org/10.1200/JCO.2019.37.15_suppl.4130.
- Zhu J, Thompson CB. Metabolic regulation of cell growth and proliferation. Nat Rev Mol Cell Biol. 2019 Jul;20(7):436–450.
- Stega J, Noel MS, Vandell AG, et al. A first-in-human study of the novel metabolism-based anti-cancer agent SM-88 in subjects with advanced metastatic cancer. Invest New Drugs. 2020 Apr;38(2):392–401. DOI:https://doi.org/10.1007/s10637-019-00758-8.
- Chung V, Chawla SP, Dong H, et al. Phase II/III study of SM-88 in patients with metastatic pancreatic cancer. J clin oncol. 2021;39(3_suppl):437. DOI:https://doi.org/10.1200/JCO.2021.39.3_suppl.437.
- Noel MS, Wang-Gillam A, Ocean AJ, et al. SM-88 therapy in high risk poor prognosis pancreatic cancer (PDAC). J clin oncol. 2019;15_suppl: 37.e15714
- Philip PA, Buyse ME, Alistar AT, et al. A phase III open-label trial to evaluate efficacy and safety of CPI-613 plus modified FOLFIRINOX (mFFX) versus FOLFIRINOX (FFX) in patients with metastatic adenocarcinoma of the pancreas. Future Oncol. 2019 Oct;15(28):3189–3196. DOI:https://doi.org/10.2217/fon-2019-0209.
- Lee KC, Maturo C, Perera CN, et al. Translational assessment of mitochondrial dysfunction of pancreatic cancer from in vitro gene microarray and animal efficacy studies, to early clinical studies, via the novel tumor-specific anti-mitochondrial agent, CPI-613. Ann Transl Med. 2014 Sep;2(9):91. DOI:https://doi.org/10.3978/j.issn.2305-5839.2014.05.08.
- Zachar Z, Marecek J, Maturo C, et al. Non-redox-active lipoate derivates disrupt cancer cell mitochondrial metabolism and are potent anticancer agents in vivo. J Mol Med (Berl). 2011 Nov;89(11):1137–1148. DOI:https://doi.org/10.1007/s00109-011-0785-8.
- Alistar A, Morris BB, Desnoyer R, et al. Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial. Lancet Oncol. 2017 Jun;18(6):770–778. DOI:https://doi.org/10.1016/S1470-2045(17)30314-5.
- Rafael pharmaceuticals provides update on pivotal phase 3 clinical trial in patients with metastatic pancreatic cancer and interim analysis of pivotal phase 3 clinical trial in patients with relapsed or refractory acute myeloid leukemia [internet]. Globe Newswire; 2021 [cited December 17, 2021]
- Bachet JB, Gay F, Maréchal R, et al. Asparagine synthetase expression and phase i study with l-asparaginase encapsulated in red blood cells in patients with pancreatic adenocarcinoma. Pancreas. 2015 Oct;44(7):1141–1147. DOI:https://doi.org/10.1097/MPA.0000000000000394.
- Burke PW, Hoelzer D, Park JH, et al. Managing toxicities with asparaginase-based therapies in adult ALL: summary of an ESMO open-cancer horizons roundtable discussion. ESMO Open. 2020 Oct;5(5):e000858. DOI:https://doi.org/10.1136/esmoopen-2020-000858.
- Hammel P, Fabienne P, Mineur L, et al. Erythrocyte-encapsulated asparaginase (eryaspase) combined with chemotherapy in second-line treatment of advanced pancreatic cancer: an open-label, randomized phase iib trial. Eur J Cancer. 2020 Jan;124:91–101.
- Whatcott CJ, Diep CH, Jiang P, et al. Desmoplasia in primary tumors and metastatic lesions of pancreatic cancer. Clin Cancer Res. 2015 Aug 1;21(15):3561–3568.
- Van Cutsem E, Tempero MA, Sigal D, et al. Randomized phase iii trial of pegvorhyaluronidase alfa with nab-paclitaxel plus gemcitabine for patients with hyaluronan-high metastatic pancreatic adenocarcinoma. J Clin Oncol. 2020 Sep 20;38(27):3185–3194.
- Cutsem EV, Lenz H-J, Furuse J, et al. Evofosfamide (TH-302) in combination with gemcitabine in previously untreated patients with metastatic or locally advanced unresectable pancreatic ductal adenocarcinoma: primary analysis of the randomized, double-blind phase III MAESTRO study. J clin oncol. 2016;34(4_suppl):193. DOI:https://doi.org/10.1200/jco.2016.34.4_suppl.193.
- Froeling FE, Feig C, Chelala C, et al. Retinoic acid-induced pancreatic stellate cell quiescence reduces paracrine Wnt-β-catenin signaling to slow tumor progression. Gastroenterology. 2011 Oct;141(4):1486–97, 1497.e1-14. DOI:https://doi.org/10.1053/j.gastro.2011.06.047.
- Kocher HM, Basu B, Froeling FEM, et al. Phase I clinical trial repurposing all-trans retinoic acid as a stromal targeting agent for pancreatic cancer. Nat Commun. 2020 Sep 24;11(1):4841.
- Beatty GL, Chiorean EG, Fishman MP, et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science. 2011 Mar 25;331(6024):1612–1616.
- Beatty GL, Torigian DA, Chiorean EG, et al. A phase I study of an agonist CD40 monoclonal antibody (CP-870,893) in combination with gemcitabine in patients with advanced pancreatic ductal adenocarcinoma. Clin Cancer Res. 2013 Nov 15;19(22):6286–6295.
- Richeldi L, Fernández Pérez ER, Costabel U, et al. Pamrevlumab, an anti-connective tissue growth factor therapy, for idiopathic pulmonary fibrosis (PRAISE): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Respir Med. 2020 Jan;8(1):25–33. DOI:https://doi.org/10.1016/S2213-2600(19)30262-0.
- Picozzi V, Alseidi A, Winter J, et al. Gemcitabine/nab-paclitaxel with pamrevlumab: a novel drug combination and trial design for the treatment of locally advanced pancreatic cancer. ESMO Open. 2020 Aug;5(4):4. DOI:https://doi.org/10.1136/esmoopen-2019-000668.
- Li Y, Rogoff HA, Keates S, et al. Suppression of cancer relapse and metastasis by inhibiting cancer stemness. Proc Natl Acad Sci U S A. 2015 Feb 10;112(6):1839–1844.
- Yuan J, Zhang F, Niu R. Multiple regulation pathways and pivotal biological functions of STAT3 in cancer. Sci Rep. 2015 Dec 3;5(1):17663.
- Kamisawa T, Wood LD, Itoi T, et al. Pancreatic cancer. Lancet. 2016 Jul 2;388(10039):73–85.
- Canon J, Rex K, Saiki AY, et al. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. Nature. 2019 Nov;575(7781):217–223. DOI:https://doi.org/10.1038/s41586-019-1694-1.
- Hong DS, Fakih MG, Strickler JH, et al. KRAS(G12C) inhibition with sotorasib in advanced solid tumors. N Engl J Med. 2020 Sep 24;383(13):1207–1217.
- Blair HA. Sotorasib: first approval. Drugs. 2021 Sep;81(13):1573–1579.
- Merz V, Gaule M, Zecchetto C, et al. Targeting KRAS: the elephant in the room of epithelial cancers. Front Oncol. 2021;11:638360.
- Kinsey CG, Camolotto SA, Boespflug AM, et al. Protective autophagy elicited by RAF→MEK→ERK inhibition suggests a treatment strategy for RAS-driven cancers. Nat Med. 2019 Apr;25(4):620–627. DOI:https://doi.org/10.1038/s41591-019-0367-9.
- Pishvaian MJ, Bender RJ, Halverson D, et al. Molecular profiling of patients with pancreatic cancer: initial results from the know your tumor initiative. Clin Cancer Res. 2018 Oct 15;24(20):5018–5027.
- Hong DS, DuBois SG, Kummar S, et al. Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials. Lancet Oncol. 2020 Apr;21(4):531–540. DOI:https://doi.org/10.1016/S1470-2045(19)30856-3.
- Sohal DPS, Kennedy EB, Cinar P, et al. Metastatic pancreatic cancer: ASCO guideline update. J Clin Oncol. 2020 Aug 5:Jco2001364. DOIhttps://doi.org/10.1200/JCO.20.01364.
- Jones MR, Williamson LM, Topham JT, et al. NRG1 gene fusions are recurrent, clinically actionable gene rearrangements in kras wild-type pancreatic ductal adenocarcinoma. Clin Cancer Res. 2019 Aug 1;25(15):4674–4681.
- Schram A, Macarulla T, O’Reilly E, et al. P86.08 phase 2 study of zenocutuzumab (MCLA-128), a bispecific HER2/HER3 antibody in NRG1 fusion-positive advanced solid tumors. J Thorac Oncol. 2021 Mar 01;16(3 Supplement):S675.
- Zenocutuzumab Shines in PDAC . Cancer Discov. 2021;11(8):1864.
- Casolino R, Paiella S, Azzolina D, et al. Homologous recombination deficiency in pancreatic cancer: a systematic review and prevalence meta-analysis. J Clin Oncol. 2021 Aug 10;39(23):2617–2631.
- Wattenberg MM, Asch D, Yu S, et al. Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutation. Br J Cancer. 2020 Feb;122(3):333–339. DOI:https://doi.org/10.1038/s41416-019-0582-7.
- Sunada S, Nakanishi A, Miki Y. Crosstalk of DNA double-strand break repair pathways in poly(ADP-ribose) polymerase inhibitor treatment of breast cancer susceptibility gene 1/2-mutated cancer. Cancer Sci. 2018 Apr;109(4):893–899.
- Golan T, Hammel P, Reni M, et al. Overall survival from the phase 3 POLO trial: maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. J clin oncol. 2021;39(3_suppl):378.
- Golan T, Hammel P, Reni M, et al. Maintenance olaparib for germline brca-mutated metastatic pancreatic cancer. N Engl J Med. 2019 Jul 25;381(4):317–327.
- O’Reilly EM, Lee JW, Zalupski M, et al. Randomized, multicenter, phase ii trial of gemcitabine and cisplatin with or without veliparib in patients with pancreas adenocarcinoma and a germline BRCA/PALB2 mutation. J Clin Oncol. 2020 May 1;38(13):1378–1388.
- Wang Z, Sun K, Xiao Y, et al. Niraparib activates interferon signaling and potentiates anti-PD-1 antibody efficacy in tumor models. Sci Rep. 2019 Feb 12;9(1):1853.
- Vikas P, Borcherding N, Chennamadhavuni A, et al. Therapeutic potential of combining PARP inhibitor and immunotherapy in solid tumors. Front Oncol. 2020;10:570.
- Wu Z, Cui P, Tao H, et al. The synergistic effect of PARP inhibitors and immune checkpoint inhibitors. Clin Med Insights Oncol. 2021;15:1179554921996288.
- Jiao S, Xia W, Yamaguchi H, et al. PARP inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression. Clin Cancer Res. 2017 Jul 15;23(14):3711–3720.
- Balachandran VP, Beatty GL, Dougan SK. Broadening the impact of immunotherapy to pancreatic cancer: challenges and opportunities. Gastroenterology. 2019 May;156(7):2056–2072.
- Royal RE, Levy C, Turner K, et al. Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. J Immunother. 2010 Oct;33(8):828–833. DOI:https://doi.org/10.1097/CJI.0b013e3181eec14c.
- Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012 Jun 28;366(26):2455–2465.
- O’Reilly EM, Oh DY, Dhani N, et al. Durvalumab with or without tremelimumab for patients with metastatic pancreatic ductal adenocarcinoma: a phase 2 randomized clinical trial. JAMA Oncol. 2019 Oct 1;5(10):1431–1438.
- Naing A, Powderly JD, Falchook G, et al. Abstract CT177: epacadostat plus durvalumab in patients with advanced solid tumors: preliminary results of the ongoing, open-label, phase I/II ECHO-203 study. Cancer Res. 2018;78(113Supplement):CT177–CT177.
- Wang W, Sun Q. Novel targeted drugs approved by the NMPA and FDA in 2019. Signal Transduct Target Ther. 2020 May 08;5(1):65.
- Fukumura D, Kloepper J, Amoozgar Z, et al. Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. Nat Rev Clin Oncol. 2018 May;15(5):325–340. DOI:https://doi.org/10.1038/nrclinonc.2018.29.
- Ebert PJR, Cheung J, Yang Y, et al. MAP kinase inhibition promotes t cell and anti-tumor activity in combination with pd-l1 checkpoint blockade. Immunity. 2016 Mar 15;44(3):609–621.
- Türeci Ӧ, Mitnacht-Kraus R, Wöll S, et al. Characterization of zolbetuximab in pancreatic cancer models. Oncoimmunology. 2019;8(1):e1523096. DOI:https://doi.org/10.1080/2162402X.2018.1523096.
- Wöll S, Schlitter AM, Dhaene K, et al. Claudin 18.2 is a target for IMAB362 antibody in pancreatic neoplasms. Int J Cancer. 2014 Feb 1;134(3):731–739.
- Chow MT, Luster AD. Chemokines in cancer. Cancer Immunol Res. 2014 Dec;2(12):1125–1131.
- Singh SK, Mishra MK, Eltoum IA, et al. CCR5/CCL5 axis interaction promotes migratory and invasiveness of pancreatic cancer cells. Sci Rep. 2018 Jan 22;8(1):1323.
- Huang H, Zepp M, Georges RB, et al. The CCR5 antagonist maraviroc causes remission of pancreatic cancer liver metastasis in nude rats based on cell cycle inhibition and apoptosis induction. Cancer Lett. 2020 Apr 1;474:82–93. DOI:https://doi.org/10.1016/j.canlet.2020.01.009.
- Le D, Gutierrez ME, Saleh M, et al. Abstract CT124: a phase Ib/II study of BMS-813160, a CC chemokine receptor (CCR) 2/5 dual antagonist, in combination with chemotherapy or nivolumab in patients (pts) with advanced pancreatic or colorectal cancer. Cancer Res. 2018;78(13 Supplement):CT124–CT124.
- Chen L, Fan J, Chen H, et al. The IL-8/CXCR1 axis is associated with cancer stem cell-like properties and correlates with clinical prognosis in human pancreatic cancer cases. Sci Rep. 2014 Aug 1;4(1):5911.
- Waugh DJJDJ, Wilson C. The interleukin-8 pathway in cancer. Clin Cancer Res. 2008 Nov 1;14(21):6735–6741.
- Fu S, Chen X, Lin HJ, et al. Inhibition of interleukin 8/C‑X-C chemokine receptor 1,/2 signaling reduces malignant features in human pancreatic cancer cells. Int J Oncol. 2018 Jul;53(1):349–357. DOI:https://doi.org/10.3892/ijo.2018.4389.
- Jin L, Tao H, Karachi A, et al. CXCR1- or CXCR2-modified CAR T cells co-opt IL-8 for maximal antitumor efficacy in solid tumors. Nat Commun. 2019 Sep 5;10(1):4016.
- Daniel SK, Seo YD, Pillarisetty VG. The CXCL12-CXCR4/CXCR7 axis as a mechanism of immune resistance in gastrointestinal malignancies. Semin Cancer Biol. 2020 Oct;65:176–188.
- Biasci D, Smoragiewicz M, Connell CM, et al. CXCR4 inhibition in human pancreatic and colorectal cancers induces an integrated immune response. Proc Natl Acad Sci U S A. 2020 Nov 17;117(46):28960–28970.
- Singh S, Srivastava SK, Bhardwaj A, et al. CXCL12-CXCR4 signalling axis confers gemcitabine resistance to pancreatic cancer cells: a novel target for therapy. Br J Cancer. 2010 Nov 23;103(11):1671–1679.
- Bockorny B, Semenisty V, Macarulla T, et al. BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial. Nat Med. 2020 Jun;26(6):878–885. DOI:https://doi.org/10.1038/s41591-020-0880-x.
- Bouchkouj N, Kasamon YL, de Claro RA, et al. FDA approval summary: axicabtagene ciloleucel for relapsed or refractory large b-cell lymphoma. Clin Cancer Res. 2019 Mar 15;25(6):1702–1708.
- O’Leary MC, Lu X, Huang Y, et al. FDA approval summary: tisagenlecleucel for treatment of patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. Clin Cancer Res. 2019 Feb 15;25(4):1142–1146.
- Jacobson CA, Maus MV. C(h)AR-ting a new course in incurable lymphomas: CAR T cells for mantle cell and follicular lymphomas. Blood Adv. 2020;4(22):5858–5862.
- Su CT, Ye JC. Emerging therapies for relapsed/refractory multiple myeloma: CAR-T and beyond. J Hematol Oncol. 2021 jul 23;14(1):115.
- Munshi NC, Anderson LD Jr., Shah N, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021 Feb 25;384(8):705–716.
- Zhang H, Ye ZL, Yuan ZG, et al. New strategies for the treatment of solid tumors with CAR-T cells. Int J Biol Sci. 2016;12(6):718–729. DOI:https://doi.org/10.7150/ijbs.14405.
- Thakur A, Ung J, Tomaszewski EN, et al. Priming of pancreatic cancer cells with bispecific antibody armed activated T cells sensitizes tumors for enhanced chemoresponsiveness. Oncoimmunology. 2021 Jun 1;10(1):1930883.
- Argani P, Iacobuzio-Donahue C, Ryu B, et al. Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). Clin Cancer Res. 2001 Dec;7(12):3862–3868.
- Pastan I, Hassan R. Discovery of mesothelin and exploiting it as a target for immunotherapy. Cancer Res. 2014 Jun 1;74(11):2907–2912.
- Zhao Y, Moon E, Carpenito C, et al. Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor. Cancer Res. 2010 Nov 15;70(22):9053–9061.
- Beatty GL, O’Hara MH, Lacey SF, et al. Activity of mesothelin-specific chimeric antigen receptor t cells against pancreatic carcinoma metastases in a phase 1 trial. Gastroenterology. 2018 Jul;155(1):29–32. DOI:https://doi.org/10.1053/j.gastro.2018.03.029.
- Haas AR, Tanyi JL, O’Hara MH, et al. Phase I study of lentiviral-transduced chimeric antigen receptor-modified t cells recognizing mesothelin in advanced solid cancers. Mol Ther. 2019 Nov 6;27(11):1919–1929.
- Yamaguchi K, Enjoji M, Tsuneyoshi M. Pancreatoduodenal carcinoma: a clinicopathologic study of 304 patients and immunohistochemical observation for CEA and CA19-9. J Surg Oncol. 1991 Jul;47(3):148–154.
- Katz SC, Burga RA, McCormack E, et al. Phase I hepatic immunotherapy for metastases study of intra-arterial chimeric antigen receptor-modified t-cell therapy for cea+ liver metastases. Clin Cancer Res. 2015 Jul 15;21(14):3149–3159.
- Katz SC, Moody AE, Guha P, et al. HITM-SURE: hepatic immunotherapy for metastases phase Ib anti-CEA CAR-T study utilizing pressure enabled drug delivery. J Immunother Cancer. 2020 Aug;8(2):e001097. DOI:https://doi.org/10.1136/jitc-2020-001097.
- Katz SC, Hardaway J, Prince E, et al. HITM-SIR: phase Ib trial of intraarterial chimeric antigen receptor T-cell therapy and selective internal radiation therapy for CEA(+) liver metastases. Cancer Gene Ther. 2020 May;27(5):341–355. DOI:https://doi.org/10.1038/s41417-019-0104-z.
- Katari UL, Keirnan JM, Worth AC, et al. Engineered T cells for pancreatic cancer treatment. HPB (Oxford). 2011 Sep;13(9):643–650. DOI:https://doi.org/10.1111/j.1477-2574.2011.00344.x.
- Abate-Daga D, Lagisetty KH, Tran E, et al. A novel chimeric antigen receptor against prostate stem cell antigen mediates tumor destruction in a humanized mouse model of pancreatic cancer. Hum Gene Ther. 2014 Dec;25(12):1003–1012. DOI:https://doi.org/10.1089/hum.2013.209.
- Mohammed S, Sukumaran S, Bajgain P, et al. Improving chimeric antigen receptor-modified t cell function by reversing the immunosuppressive tumor microenvironment of pancreatic cancer. Mol Ther. 2017 Jan 4;25(1):249–258.
- Duong MT, Collinson-Pautz MR, Morschl E, et al. Two-dimensional regulation of CAR-T cell therapy with orthogonal switches. Mol Ther Oncolytics. 2019 Mar;29(12):124–137. DOI:https://doi.org/10.1016/j.omto.2018.12.009.
- Tobita K, Kijima H, Dowaki S, et al. Epidermal growth factor receptor expression in human pancreatic cancer: significance for liver metastasis. Int J Mol Med. 2003 Mar;11(3):305–309.
- Liu Y, Guo Y, Wu Z, et al. Anti-EGFR chimeric antigen receptor-modified T cells in metastatic pancreatic carcinoma: a phase I clinical trial. Cytotherapy. 2020 Oct;22(10):573–580. DOI:https://doi.org/10.1016/j.jcyt.2020.04.088.
- Reusch U, Sundaram M, Davol PA, et al. Anti-CD3 x anti-epidermal growth factor receptor (EGFR) bispecific antibody redirects T-cell cytolytic activity to EGFR-positive cancers in vitro and in an animal model. Clin Cancer Res. 2006 Jan 1;12(1):183–190.
- Lum LG, Thakur A, Choi M, et al. Clinical and immune responses to anti-CD3 x anti-EGFR bispecific antibody armed activated T cells (EGFR BATs) in pancreatic cancer patients. Oncoimmunology. 2020 Jun 10;9(1):1773201.
- Zhu H, Li T, Du Y, et al. Pancreatic cancer: challenges and opportunities. BMC Med. 2018;16(1):214. DOI:https://doi.org/10.1186/s12916-018-1215-3.
- Lesch S, Blumenberg V, Stoiber S, et al. T cells armed with C-X-C chemokine receptor type 6 enhance adoptive cell therapy for pancreatic tumours. Nat Biomed Eng. 2021 June 3;5(11):1246–1260.
- Cadilha BL, Benmebarek MR, Dorman K, et al. Combined tumor-directed recruitment and protection from immune suppression enable CAR T cell efficacy in solid tumors. Sci Adv. 2021 June;7(24):
- Lee YG, Marks I, Srinivasarao M, et al. Use of a single CAR T cell and several bispecific adapters facilitates eradication of multiple antigenically different solid tumors. Cancer Res. 2019 Jan 15;79(2):387–396.
- Lee YG, Chu H, Lu Y, et al. Regulation of CAR T cell-mediated cytokine release syndrome-like toxicity using low molecular weight adapters. Nat Commun. 2019 Jun 18;10(1):2681.